Carafate liquid (sucralfate oral suspension) costs significantly more than the tablet form of the same medication, and the reasons come down to a combination of manufacturing complexity, limited market competition, and insurance coverage gaps. Even with generic versions now available, the suspension consistently runs several times the price of tablets at most pharmacies.
Liquid Suspensions Cost More to Make
Pressing a drug into a tablet is relatively straightforward. Keeping that same drug evenly distributed in a liquid is not. Sucralfate suspension requires careful control of two physical properties that tablets don’t have to worry about: sedimentation (the active ingredient settling to the bottom) and particle size growth (the drug crystals clumping together over time). Both are classified as critical quality attributes by the FDA, meaning manufacturers must continuously test for them throughout production and shelf life.
The formulation itself is more involved than a simple tablet. The suspension contains roughly a dozen ingredients, including thickening agents, preservatives, flavoring, and anti-foaming compounds, all of which must be balanced to keep the drug stable and uniformly mixed. Dissolution testing for the suspension is also unusually complex. Instead of measuring how quickly the drug dissolves like a standard tablet test, the FDA requires manufacturers to measure the release of aluminum ions in a specific acid environment, mimicking stomach conditions. All of this adds time, equipment, and quality control costs that don’t apply to the tablet version.
Generic Competition Took Decades to Arrive
The brand-name Carafate suspension, manufactured by AbbVie, dominated the market for years with little competition. The first generic sucralfate suspensions weren’t approved by the FDA until December 2019. Since then, several generic manufacturers have entered the market, including Amneal, Mylan, Glenmark, and others, with approvals continuing as recently as 2026.
More generic competitors usually drives prices down, and it has to some extent. But the liquid formulation’s manufacturing hurdles create a higher barrier to entry than tablets, which have had cheap generics available for much longer. Fewer manufacturers means less price pressure. And notably, the FDA has stated that equivalence between the oral suspension and the tablets “has not been demonstrated,” which means the two forms aren’t considered interchangeable. A prescription written for the liquid can’t simply be swapped for cheaper tablets at the pharmacy counter.
Insurance Often Covers It Differently
Many insurance formularies treat the tablet and suspension as separate products with different coverage tiers. In the VA system, for example, sucralfate tablets sit on a Tier 2 copay level. While the suspension is listed as a formulary item, its practical coverage and out-of-pocket cost can differ. Private insurers may place the liquid on a higher tier, require prior authorization, or exclude it from preferred drug lists entirely, leaving patients responsible for more of the cost.
When your insurance doesn’t cover the suspension or places it on a non-preferred tier, you’re exposed to a price that reflects all the manufacturing complexity described above, without the cushion of negotiated insurer rates. This is the scenario most people encounter when they see a shockingly high price at the pharmacy.
Who Actually Needs the Liquid Form
The liquid version is FDA-approved for the short-term treatment (up to 8 weeks) of active duodenal ulcers, taken as 10 mL four times a day on an empty stomach. Some patients genuinely need the liquid rather than the tablet: people with swallowing difficulties, those with esophageal conditions where the liquid can coat tissue on the way down, or patients who can’t crush tablets for medical reasons.
If you don’t fall into one of those categories, it’s worth asking your prescriber whether the tablet form would work for your situation. The tablets are dramatically cheaper, and while the FDA hasn’t declared formal equivalence between the two forms, both contain the same active ingredient at the same dose.
A Compounding Option Exists
Some pharmacies can compound a sucralfate suspension from tablets, which can cut the cost substantially. The process involves dissolving tablets in purified water and sorbitol, creating a liquid that must be refrigerated and shaken before each dose. This compounded version lacks the preservatives and precise stability testing of the commercial product, so it has a shorter shelf life and requires more careful handling. Not every pharmacy offers compounding services, and not every insurer will cover a compounded preparation, but it’s an option worth discussing if the commercial suspension’s price is a barrier.
How to Reduce Your Cost
If you need the liquid form specifically, a few strategies can help. First, ask your pharmacist to run the prescription through a discount card or coupon program. Sites like GoodRx and RxSaver often show significant price variation between pharmacies for generic sucralfate suspension. Second, request the generic by name. With nearly a dozen manufacturers now approved, your pharmacy may be able to order a lower-cost generic version. Third, if your insurance requires prior authorization, have your prescriber submit one, especially if there’s a documented medical reason you can’t take the tablet. Insurers are more likely to cover the suspension at a lower tier when there’s clinical justification on file.